Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: iCAD Inc

Market Cap 106M 92.27M 85.35M 79.66M 150M 9.98B 151M 1.01B 395M 4.91B 396M 388M 17.04B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.55M 71.73M 66.95M 126M 8.39B 127M 852M 332M 4.12B 333M 326M 14.32B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%-2.05%+16.62%-12.17% 172B
-0.94%-3.26%-20.89%+22.99% 143B
+0.58%-1.61%-9.27%-24.62% 126B
-2.12%-5.20%-56.24%-18.87% 65.89B
-1.69%-0.46%+16.32%-5.97% 49.45B
+0.79%-1.32%-25.37%-31.90% 44.05B
-0.45%-3.14%+9.46%+6.58% 35.72B
+0.79%+0.14%+4.56%+37.65% 35.18B
-1.54%-6.36%-14.93%-24.40% 27.58B
Average -0.52%-2.49%-8.86%-5.63% 77.68B
Weighted average by Cap. -0.43%-2.43%-7.46%-5.69%

Financials

2023 2024
Net sales 17.32M 15.13M 14M 13.06M 24.53M 1.64B 24.71M 166M 64.72M 805M 65.02M 63.61M 2.8B 19.61M 17.13M 15.85M 14.79M 27.77M 1.85B 27.97M 188M 73.28M 911M 73.62M 72.02M 3.16B
Net income -4.85M -4.24M -3.92M -3.66M -6.86M -458M -6.91M -46.55M -18.11M -225M -18.2M -17.8M -782M -5.62M -4.91M -4.54M -4.24M -7.95M -531M -8.01M -53.94M -20.99M -261M -21.09M -20.63M -906M
Net Debt -21.21M -18.53M -17.14M -16M -30.04M -2B -30.26M -204M -79.26M -985M -79.63M -77.9M -3.42B -16.84M -14.72M -13.61M -12.71M -23.85M -1.59B -24.03M -162M -62.95M -783M -63.24M -61.87M -2.72B
Logo iCAD Inc
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!